T. Rowe Price Associates
CODX

T. Rowe Price Associates’s Co-Diagnostics CODX Stock Holding History

T. Rowe Price Associates’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,180
Closed -$344K – 2991
2021
Q3 		$344K Sell
1,180
-140
-11% -$40.9K ﹤0.01% 2529
2021
Q2 		$327K Sell
1,320
-264
-17% -$67.9K ﹤0.01% 2562
2021
Q1 		$453K Sell
1,584
-165
-9% -$65.9K ﹤0.01% 2420
2020
Q4 		$488K Buy
+1,749
New +$648K ﹤0.01% 2250

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates's CODX Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Co-Diagnostics (CODX) in Q4 2021, closing a stake of 1,180 shares — an estimated $344K sold.

T. Rowe Price Associates first reported a position in CODX in Q4 2020 and held it in 4 quarters. The position peaked at $488K in Q4 2020. 77 funds tracked by Wall St. Rank hold CODX as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Co-Diagnostics position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,180 Co-Diagnostics shares in Q4 2021, an estimated $344K.
  • T. Rowe Price Associates first reported a position in Co-Diagnostics in Q4 2020 and held it in 4 quarters.
  • T. Rowe Price Associates's Co-Diagnostics position peaked at $488K in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.